疏血通联合依达拉奉治疗进展性脑卒中的疗效分析

姜永飞

长春市人民医院神经内科,吉林长春130051

[摘要]目的分析疏血通联合依达拉奉治疗进展性脑卒中的临床疗效。方法整群选择2014年1月—2015年1月该院收治的进展性脑卒中患者98例，将患者随机分为治疗组、对照组，每组49例。对照组给予神经营养药物、抗血小板聚集及降压、调控血糖等对症治疗；观察组在对照组基础上加用依达拉奉30 mg+氯化钠溶液100 mL静滴，2次/d；疏血通6 mL+氯化钠溶液250 mL静滴。疗程14 d。结果治疗组:基本治愈19例（38.78%），显著进步17例（34.69%），进步8例（16.33%），总有效率89.8%；对照组基本治愈8例（16.33%），显著进步11例（22.45%），进步9例（18.37%），总有效率57.15%，两组比较差异有统计学意义（P<0.05）。结论疏血通联合依达拉奉治疗进展性脑卒中,临床疗效确切、安全性好，降低致残率、病死率,值得临床推广应用。

[关键词]疏血通；依达拉奉；进展性脑卒中

[中图分类号]R4

[文献标识码]A

[文章编号]1674-0742（2015）10（a）－0147-02

[作者简介]姜永飞(1972.10-),男,吉林长春人，硕士，主治医师，研究方向：脑血管病临床治疗。

Abstract[]Objective To evaluate the clinical effect of Shuxuetong injection combined with edaravone in the treatment of progres鄄sive stroke.Methods From January 2014 to January 2015, 98 patients with progressive stroke were randomly divided into treat鄄ment group and control group, 49 cases in each group.The control group was given symptomatic treatment of neural nutrition drugs, anti platelet aggregation and blood pressure, control blood sugar; observation group in the control group on the basis of the intravenous infusion of edaravone 30 mg + sodium chloride solution of 100 mL, 2 times/day; Shuxuetong 6 mL+ solution of sodium chloride 250 mL intravenous drip.14 days of treatment.Results The treatment group: cure in 19 cases (38.78%), significant progress in 17 cases (34.69%), 8 cases of progress (16.33%).The total effective rate is 89.8%; the control group cured in 8 cases (16.33%), significant progress has been made in 11 cases (22.45%), progress in 9 cases (18.37%), the total efficiency of 57.15%, the difference between the two groups is significant (P<0.05).Conclusion Stroke in progression of Shuxuetong injection combined with edaravone in treatment, clinical curative effect is exact, safe, reduce disability rate and fatality rate, worthy of clinical application.[Key words]Shuxuetong; Edaravone; Progressive stroke

收稿日期：（2015-07-06）

Analysis of Curative Effect of Shuxuetong Injection Combined with Edar鄄avone in the Treatment of Progressive Stroke

JIANG Yong-fei

Department of Neurology, Changchun people's Hospital, Changchun, Jilin Province, 130051 China

进展性卒中是指缺血性卒中后神经功能缺失症状在一段时间内呈渐进性加重，该病发病率及致残致死率高，严重危害患者健康[1-4]。依达拉奉是一种脑保护剂，可抑制脂质过氧化反应、降低羟自由基浓度，改善神经、脑细胞功能[5]。蚓激酶和水蛭素为疏血通的主要成分，凝血酶可与水蛭素特异性结合，阻断凝血酶水解蛋白的功能，从而抑制血小板释放，同时水蛭素可激活体内纤溶系统，实现抗凝、抗栓，蚓激酶亦可激活纤溶酶原，又可溶解纤维蛋白[8-10]。该院于2014年1月—2015年1月采用疏血通联合依达拉奉对进展性脑卒中患者进行治疗,获得满意疗效，现报道如下。……